Physicians, scientists and advanced practice providers from virtually every medical specialty and scientific field heard their colleagues on the leading edge of this work highlight the hopes and challenges of precision medicine for the nearly 50 million people in the U.S. with disorders of immunity.
One of the most feared risks of immunosuppressive and biologic therapeutics is the development of progressive multifocal leukoencephelopathy. A risk assessment tool is available.
Hepatitis C infection has presented a profound challenge to physicians— including rheumatologists, dermatologists and gastroenterologists — caring for patients with immune-mediated inflammatory diseases.
Individuals with clinically unapparent HBV and concomitant immune-mediated inflammatory diseases (IMIDs) (e.g., rheumatoid arthritis, psoriasis, inflammatory bowel disease and others) are particularly vulnerable to HBV reactivation when immunosuppressed.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
We know more about spondyloarthritis than ever, but where are the patients?
Rheumatologists eagerly await the day when we do not have to juggle protection against herpes zoster with the risks of giving a live vaccine to patients on high-dose prednisone and/or biologic DMARDs.